Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit
Status
Conditions
Treatments
Details and patient eligibility
About
The investigators will randomize smokers to receive 1) Varenicline + smoking cessation/reduction counseling or 2) Placebo pill + smoking cessation/reduction counseling. Neither the participants nor the research therapists/evaluators will know to which condition (active or placebo pill) the participants have been assigned i.e., a double-blind study). The medication and weekly counseling will occur for 28 days. Participants will complete assessment measures just before the start of treatment (baseline), at the end-of-treatment, at 1-month, 3-month, and at 6-months to determine if there are differences in tobacco use between treatment groups.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Must smoke at least 10 cigarettes per day for past 6-months
- Must have a working cellular or land-line phone
Exclusion criteria
- Must not be thinking of quitting in the next 30 days, but be interested in cutting down- Must not regularly (more than 1x/month) use tobacco products other than cigarettes
- Must not be currently receiving tobacco dependence treatment counseling
- Must not currently be taking varenicline, bupropion, nortriptyline, or any nicotine preparations (gum, lozenge, patch, spray, inhaler)
- Must not have positive screen on SCID-I/NP Psychotic Screen
- Must have no contraindications to using varenicline, including pregnancy, as measured by Medical History Form
Trial design
Primary purpose
Allocation
Interventional model
Masking
73 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal